Involvement of the PRDX family and its clinical functions in different types of gastrointestinal cancer (Review)
- Authors:
- Zhou Zhang
- Yujie Wang
- Yuhao Liu
- Haizhen Wu
- Xiaopeng Xu
- Kai Wang
- Chen He
- Chen Qian
-
Affiliations: Department of Clinical Laboratory, Xishan People's Hospital of Wuxi City, Wuxi, Jiangsu 214105, P.R. China, College of Medicine, Yangzhou University, Yangzhou, Jiangsu 225001, P.R. China, Department of Applied Biology, School of Biotechnology, East China University of Science and Technology, Shanghai 200237, P.R. China, Nuclear Medicine Department, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China - Published online on: June 4, 2025 https://doi.org/10.3892/or.2025.8923
- Article Number: 90
This article is mentioned in:
Abstract
Wang S, Zheng R, Li J, Zeng H, Li L, Chen R, Sun K, Han B, Bray F, Wei W and He J: Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: A population-based systematic analysis of GLOBOCAN. Lancet Gastroenterol Hepatol. 9:229–237. 2024. View Article : Google Scholar : PubMed/NCBI | |
Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI | |
Huang J, Lucero-Prisno DE III, Zhang L, Xu W, Wong SH, Ng SC and Wong MCS: Updated epidemiology of gastrointestinal cancers in East Asia. Nat Rev Gastroenterol Hepatol. 20:271–287. 2023. View Article : Google Scholar : PubMed/NCBI | |
Forman HJ and Zhang H: Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy. Nat Rev Drug Discov. 20:689–709. 2021. View Article : Google Scholar : PubMed/NCBI | |
Mittler R: ROS are good. Trends Plant Sci. 22:11–19. 2017. View Article : Google Scholar : PubMed/NCBI | |
Holmström KM and Finkel T: Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol. 15:411–421. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhao W, Zhuang P, Chen Y, Wu Y, Zhong M and Lun Y: ‘Double-edged sword’ effect of reactive oxygen species (ROS) in tumor development and carcinogenesis. Physiol Res. 72:301–307. 2023. View Article : Google Scholar : PubMed/NCBI | |
Rosini E and Pollegioni L: Reactive oxygen species as a double-edged sword: The role of oxidative enzymes in antitumor therapy. Biofactors. 48:384–399. 2022. View Article : Google Scholar : PubMed/NCBI | |
Agidigbi TS and Kim C: Reactive oxygen species in osteoclast differentiation and possible pharmaceutical targets of ROS-mediated osteoclast diseases. Int J Mol Sci. 20:35762019. View Article : Google Scholar : PubMed/NCBI | |
Fransen M and Lismont C: Redox signaling from and to peroxisomes: Progress, challenges, and prospects. Antioxid Redox Signal. 30:95–112. 2019. View Article : Google Scholar : PubMed/NCBI | |
Lee YJ: Knockout mouse models for peroxiredoxins. Antioxidants (Basel). 9:1822020. View Article : Google Scholar : PubMed/NCBI | |
Park MH, Jo M, Kim YR, Lee CK and Hong JT: Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases. Pharmacol Ther. 163:1–23. 2016. View Article : Google Scholar : PubMed/NCBI | |
Jeong SJ, Park JG and Oh GT: Peroxiredoxins as potential targets for cardiovascular disease. Antioxidants (Basel). 10:12442021. View Article : Google Scholar : PubMed/NCBI | |
Zhou F, Chen F, Ouyang Z, Zhu R, Zhou R, Hu W and Lu C: Functions of peroxiredoxins and their roles in autoimmune diseases. Antioxid Redox Signal. 40:329–344. 2024. View Article : Google Scholar : PubMed/NCBI | |
Gao L, Meng J, Yue C, Wu X, Su Q, Wu H, Zhang Z, Yu Q, Gao S, Fan S and Zuo L: Integrative analysis the characterization of peroxiredoxins in pan-cancer. Cancer Cell Int. 21:3662021. View Article : Google Scholar : PubMed/NCBI | |
Rodrigo DCG, Udayantha HMV, Liyanage DS, Omeka WKM, Kodagoda YK, Hanchapola HACR, Dilshan MAH, Ganepola GANP, Warnakula WADLR, Kim G, et al: Functional characterization of peroxiredoxin 5 from yellowtail clownfish (Amphiprion clarkii): Immunological expression assessment, antioxidant activities, heavy metal detoxification, and nitrosative stress mitigation. Dev Comp Immunol. 162:1052892025. View Article : Google Scholar : PubMed/NCBI | |
Prochownik EV: Functional and physical communication between oncoproteins and tumor suppressors. Cell Mol Life Sci. 62:2438–2459. 2005. View Article : Google Scholar : PubMed/NCBI | |
Wu X, Li J, Zhang H, Wang H, Yin G and Miao D: Pyrroloquinoline quinone prevents testosterone deficiency-induced osteoporosis by stimulating osteoblastic bone formation and inhibiting osteoclastic bone resorption. Am J Transl Res. 9:1230–1242. 2017.PubMed/NCBI | |
Yamada S, Al-Sharabi N, Torelli F, Volponi AA, Sandven L, Ueda M, Fristad I and Mustafa K: Harnessing the antioxidative potential of dental pulp stem cell-conditioned medium in photopolymerized GelMA hydrogels. Biomater Res. 28:00842024. View Article : Google Scholar : PubMed/NCBI | |
Xu Z, Chen Q, Zeng X, Li M and Liao J: lnc-NLC1-C inhibits migration, invasion and autophagy of glioma cells by targeting miR-383 and regulating PRDX-3 expression. Oncol Lett. 22:6402021. View Article : Google Scholar : PubMed/NCBI | |
Lv C, Huang Y, Wang Q, Wang C, Hu H, Zhang H, Lu D, Jiang H, Shen R, Zhang W and Liu S: Ainsliadimer A induces ROS-mediated apoptosis in colorectal cancer cells via directly targeting peroxiredoxin 1 and 2. Cell Chem Biol. 30:295–307.e5. 2023. View Article : Google Scholar : PubMed/NCBI | |
Walsh B, Pearl A, Suchy S, Tartaglio J, Visco K and Phelan SA: Overexpression of Prdx6 and resistance to peroxide-induced death in Hepa1-6 cells: Prdx suppression increases apoptosis. Redox Rep. 14:275–284. 2009. View Article : Google Scholar : PubMed/NCBI | |
Liu Y, Wang P, Hu W and Chen D: New insights into the roles of peroxiredoxins in cancer. Biomed Pharmacother. 164:1148962023. View Article : Google Scholar : PubMed/NCBI | |
Neumann CA and Fang Q: Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol. 7:375–380. 2007. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Zheng Q, Li P, Xu X, Zhou Y and Qian C: Expression and mechanism of PRDXs family in oral squamous cell carcinoma. Discov Oncol. 16:4152025. View Article : Google Scholar : PubMed/NCBI | |
Carini F, Mazzola M, Rappa F, Jurjus A, Geagea AG, Al Kattar S, Bou-Assi T, Jurjus R, Damiani P, Leone A and Tomasello G: Colorectal carcinogenesis: Role of oxidative stress and antioxidants. Anticancer Res. 37:4759–4766. 2017.PubMed/NCBI | |
Song JH, Han YM, Kim WH, Park JM, Jeong M, Go EJ, Hong SP and Hahm KB: Oxidative stress from reflux esophagitis to esophageal cancer: The alleviation with antioxidants. Free Radic Res. 50:1071–1079. 2016. View Article : Google Scholar : PubMed/NCBI | |
Liu Y, Hao C, Li L, Zhang H, Zha W, Ma L, Chen L and Gan J: The role of oxidative stress in the development and therapeutic intervention of hepatocellular carcinoma. Curr Cancer Drug Targets. 23:792–804. 2023. View Article : Google Scholar : PubMed/NCBI | |
Toh JWT and Wilson RB: Pathways of gastric carcinogenesis, Helicobacter pylori virulence and interactions with antioxidant systems, vitamin C and phytochemicals. Int J Mol Sci. 21:64512020. View Article : Google Scholar : PubMed/NCBI | |
Kim K, Kim IH, Lee KY, Rhee SG and Stadtman ER: The isolation and purification of a specific ‘protector’ protein which inhibits enzyme inactivation by a thiol/Fe(III)/O2 mixed-function oxidation system. J Biol Chem. 263:4704–4711. 1988. View Article : Google Scholar : PubMed/NCBI | |
Tartaglia LA, Storz G, Brodsky MH, Lai A and Ames BN: Alkyl hydroperoxide reductase from Salmonella typhimurium. Sequence and homology to thioredoxin reductase and other flavoprotein disulfide oxidoreductases. J Biol Chem. 265:10535–10540. 1990. View Article : Google Scholar : PubMed/NCBI | |
Chae HZ, Chung SJ and Rhee SG: Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem. 269:27670–27678. 1994. View Article : Google Scholar : PubMed/NCBI | |
McGonigle S, Dalton JP and James ER: Peroxidoxins: A new antioxidant family. Parasitol Today. 14:139–145. 1998. View Article : Google Scholar : PubMed/NCBI | |
Rhee SG, Chae HZ and Kim K: Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI | |
Neumann CA, Cao J and Manevich Y: Peroxiredoxin 1 and its role in cell signaling. Cell Cycle. 8:4072–4078. 2009. View Article : Google Scholar : PubMed/NCBI | |
Hall A, Nelson K, Poole LB and Karplus PA: Structure-based insights into the catalytic power and conformational dexterity of peroxiredoxins. Antioxid Redox Signal. 15:795–815. 2011. View Article : Google Scholar : PubMed/NCBI | |
Rhee SG, Woo HA, Kil IS and Bae SH: Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J Biol Chem. 287:4403–4410. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chae HZ, Robison K, Poole LB, Church G, Storz G and Rhee SG: Cloning and sequencing of thiol-specific antioxidant from mammalian brain: Alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA. 91:7017–7021. 1994. View Article : Google Scholar : PubMed/NCBI | |
Rhee SG, Kang SW, Chang TS, Jeong W and Kim K: Peroxiredoxin, a novel family of peroxidases. IUBMB Life. 52:35–41. 2001. View Article : Google Scholar : PubMed/NCBI | |
Wood ZA, Schröder E, Robin Harris J and Poole LB: Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 28:32–40. 2003. View Article : Google Scholar : PubMed/NCBI | |
Immenschuh S and Baumgart-Vogt E: Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal. 7:768–777. 2005. View Article : Google Scholar : PubMed/NCBI | |
Banmeyer I, Marchand C, Verhaeghe C, Vucic B, Rees JF and Knoops B: Overexpression of human peroxiredoxin 5 in subcellular compartments of Chinese hamster ovary cells: Effects on cytotoxicity and DNA damage caused by peroxides. Free Radic Biol Med. 36:65–77. 2004. View Article : Google Scholar : PubMed/NCBI | |
Rhee SG: Overview on peroxiredoxin. Mol Cells. 39:1–5. 2016. View Article : Google Scholar : PubMed/NCBI | |
Oberley TD, Verwiebe E, Zhong W, Kang SW and Rhee SG: Localization of the thioredoxin system in normal rat kidney. Free Radic Biol Med. 30:412–424. 2001. View Article : Google Scholar : PubMed/NCBI | |
Verdoucq L, Vignols F, Jacquot JP, Chartier Y and Meyer Y: In vivo characterization of a thioredoxin h target protein defines a new peroxiredoxin family. J Biol Chem. 274:19714–19722. 1999. View Article : Google Scholar : PubMed/NCBI | |
Ding C, Fan X and Wu G: Peroxiredoxin 1-an antioxidant enzyme in cancer. J Cell Mol Med. 21:193–202. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wen ST and Van Etten RA: The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11:2456–2467. 1997. View Article : Google Scholar : PubMed/NCBI | |
Sobin LH and Fleming ID: TNM classification of malignant tumors, fifth edition (1997). union internationale contre le cancer and the American joint committee on cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI | |
Sun HH, Li YL, Jiang H, Yin XH and Jin XL: PRDX1 influences the occurrence and progression of liver cancer by inhibiting mitochondrial apoptosis pathway. Cell J. 24:657–664. 2022.PubMed/NCBI | |
Lu E, Hu X, Pan C, Chen J, Xu Y and Zhu X: Up-regulation of peroxiredoxin-1 promotes cell proliferation and metastasis and inhibits apoptosis in cervical cancer. J Cancer. 11:1170–1181. 2020. View Article : Google Scholar : PubMed/NCBI | |
Moretton A, Kourtis S, Gañez Zapater A, Calabrò C, Espinar Calvo ML, Fontaine F, Darai E, Abad Cortel E, Block S, Pascual-Reguant L, et al: A metabolic map of the DNA damage response identifies PRDX1 in the control of nuclear ROS scavenging and aspartate availability. Mol Syst Biol. 19:e112672023. View Article : Google Scholar : PubMed/NCBI | |
Skoko JJ, Cao J, Gaboriau D, Attar M, Asan A, Hong L, Paulsen CE, Ma H, Liu Y, Wu H, et al: Redox regulation of RAD51 Cys319 and homologous recombination by peroxiredoxin 1. Redox Biol. 56:1024432022. View Article : Google Scholar : PubMed/NCBI | |
Gong F, Hou G, Liu H and Zhang M: Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma. Med Oncol. 32:4552015. View Article : Google Scholar : PubMed/NCBI | |
Gong F, Liu H, Li J, Xue L and Zhang M: Peroxiredoxin 1 is involved in disassembly of flagella and cilia. Biochem Biophys Res Commun. 444:420–426. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Wang K, Zhang J, Liu SS, Dai L and Zhang JY: Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res. 10:2863–2872. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ren P, Ye H, Dai L, Liu M, Liu X, Chai Y, Shao Q, Li Y, Lei N, Peng B, et al: Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma. Oncol Rep. 30:2297–2303. 2013. View Article : Google Scholar : PubMed/NCBI | |
Chen Q, Li J, Yang X, Ma J, Gong F and Liu Y: Prdx1 promotes the loss of primary cilia in esophageal squamous cell carcinoma. BMC Cancer. 20:3722020. View Article : Google Scholar : PubMed/NCBI | |
Song Y, Liu H, Cui C, Peng X, Wang C, Tian X and Li W: Silencing of peroxiredoxin 1 inhibits the proliferation of esophageal cancer cells and promotes apoptosis by inhibiting the activity of the PI3K/AKT pathway. Cancer Manag Res. 11:10883–10890. 2019. View Article : Google Scholar : PubMed/NCBI | |
Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, Sakata H, Matsushita K and Ochiai T: Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep. 18:867–871. 2007.PubMed/NCBI | |
An Y, Jiang J, Zhou L, Shi J, Jin P, Li L, Peng L, He S, Zhang W, Huang C, et al: Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. Cancer Lett. 521:210–223. 2021.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
Ma Q, Hui Y, Huang BR, Yang BF, Li JX, Fan TT, Gao XC, Ma DY, Chen WF and Pei ZX: Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: Development and validation based on TCGA and ICGC databases. Transl Cancer Res. 12:46–64. 2023. View Article : Google Scholar : PubMed/NCBI | |
He Y, Li S, Tang D, Peng Y, Meng J, Peng S, Deng Z, Qiu S, Liao X, Chen H, et al: Circulating peroxiredoxin-1 is a novel damage-associated molecular pattern and aggravates acute liver injury via promoting inflammation. Free Radic Biol Med. 137:24–36. 2019. View Article : Google Scholar : PubMed/NCBI | |
Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu JH, Xu GL, Ma JL, Zhong W and Jia WD: Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol. 31:7862014. View Article : Google Scholar : PubMed/NCBI | |
Cheng ML, Lu YF, Chen H, Shen ZY and Liu J: Liver expression of Nrf2-related genes in different liver diseases. Hepatobiliary Pancreat Dis Int. 14:485–491. 2015. View Article : Google Scholar : PubMed/NCBI | |
Luo L, Yao X, Xiang J, Huang F and Luo H: Identification of ferroptosis-related genes for overall survival prediction in hepatocellular carcinoma. Sci Rep. 12:100072022. View Article : Google Scholar : PubMed/NCBI | |
Aguilar-Melero P, Prieto-Álamo MJ, Jurado J, Holmgren A and Pueyo C: Proteomics in HepG2 hepatocarcinoma cells with stably silenced expression of PRDX1. J Proteomics. 79:161–171. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Wu K, Liu Y, Sun S, Shao Y, Li Q, Sui X and Duan C: UHRF2 promotes the malignancy of hepatocellular carcinoma by PARP1 mediated autophagy. Cell Signal. 109:1107822023. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Zhou P, Liu M and Pei B: Expression and prognostic role of PRDX1 in gastrointestinal cancers. J Cancer. 14:2895–2907. 2023. View Article : Google Scholar : PubMed/NCBI | |
Zhuang K, Tang H, Guo H and Yuan S: Geraniol prevents Helicobacterium pylori-induced human gastric cancer signalling by enhancing peroxiredoxin-1 expression in GES-1 cells. Microb Pathog. 174:1059372023. View Article : Google Scholar : PubMed/NCBI | |
Tan BB, Li Y, Li SJ, Zhao Q, Fan LQ, Liu QW, Zhao YJ and Zhang MY: Effect and mechanism of PRDX1 in epithelial mesenchymal transformationin of gastric cancer cells. Zhonghua Zhong Liu Za Zhi. 42:919–924. 2020.(In Chinese). PubMed/NCBI | |
Xu R, Pan J, Mei J and Zhang Q: Systematic characterization of prognostic values of peroxiredoxin family in gastric cancer. Biomed Res Int. 2020:39481832020. View Article : Google Scholar : PubMed/NCBI | |
Yu W, Wu J, Ning ZL, Liu QY and Quan RL: High expression of peroxiredoxin 1 is associated with epithelial-mesenchymal transition marker and poor prognosis in gastric cancer. Med Sci Monit. 24:2259–2270. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z and Dai DQ: MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promotor demethylation. World J Gastroenterol. 25:1224–1237. 2019. View Article : Google Scholar : PubMed/NCBI | |
Li HX, Sun XY, Yang SM, Wang Q and Wang ZY: Peroxiredoxin 1 promoted tumor metastasis and angiogenesis in colorectal cancer. Pathol Res Pract. 214:655–660. 2018. View Article : Google Scholar : PubMed/NCBI | |
Xu S, Ma Y, Tong Q, Yang J, Liu J, Wang Y, Li G, Zeng J, Fang S, Li F, et al: Cullin-5 neddylation-mediated NOXA degradation is enhanced by PRDX1 oligomers in colorectal cancer. Cell Death Dis. 12:2652021. View Article : Google Scholar : PubMed/NCBI | |
Song Y, Wang X, Sun Y, Yu N, Tian Y, Han J, Qu X and Yu X: PRDX1 inhibits ferroptosis by binding to Cullin-3 as a molecular chaperone in colorectal cancer. Int J Biol Sci. 20:5070–5086. 2024. View Article : Google Scholar : PubMed/NCBI | |
Rho JH, Qin S, Wang JY and Roehrl MHA: Proteomic expression analysis of surgical human colorectal cancer tissues: Up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res. 7:2959–2972. 2008. View Article : Google Scholar : PubMed/NCBI | |
Chu G, Li J, Zhao Y, Liu N, Zhu X, Liu Q, Wei D and Gao C: Identification and verification of PRDX1 as an inflammation marker for colorectal cancer progression. Am J Transl Res. 8:842–859. 2016.PubMed/NCBI | |
Li Y, Zhu Y, Shang FF, Xu L, Jiang D, Sun B, Zhang L, Luo C, Zhang A, Zhang H and Ding C: Discovery of urea derivatives of celastrol as selective peroxiredoxin 1 inhibitors against colorectal cancer cells. J Med Chem. 67:7176–7196. 2024. View Article : Google Scholar : PubMed/NCBI | |
Tai WC, Wong WY, Lee MM, Chan BD, Lu C and Hsiao WL: Mechanistic study of the anti-cancer effect of Gynostemma pentaphyllum saponins in the Apc(Min/+) mouse model. Proteomics. 16:1557–1569. 2016. View Article : Google Scholar : PubMed/NCBI | |
Cai CY, Zhai LL, Wu Y and Tang ZG: Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer. Eur J Surg Oncol. 41:228–235. 2015. View Article : Google Scholar : PubMed/NCBI | |
Taniuchi K, Furihata M, Hanazaki K, Iwasaki S, Tanaka K, Shimizu T, Saito M and Saibara T: Peroxiredoxin 1 promotes pancreatic cancer cell invasion by modulating p38 MAPK activity. Pancreas. 44:331–340. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhou J, Shen W, He X, Qian J, Liu S and Yu G: Overexpression of Prdx1 in hilar cholangiocarcinoma: A predictor for recurrence and prognosis. Int J Clin Exp Pathol. 8:9863–9874. 2015.PubMed/NCBI | |
Liao W, Du J, Li L, Wu X, Chen X, Feng Q, Xu L, Chen X, Liao M, Huang J, et al: CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma. J Exp Clin Cancer Res. 42:1252023. View Article : Google Scholar : PubMed/NCBI | |
Hall A, Karplus PA and Poole LB: Typical 2-Cys peroxiredoxins-structures, mechanisms and functions. FEBS J. 276:2469–2477. 2009. View Article : Google Scholar : PubMed/NCBI | |
Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, Bennett R, Bhai J, Billis K, Boddu S, et al: Ensembl 2019. Nucleic Acids Res. 47(D1): D745–D751. 2019. View Article : Google Scholar : PubMed/NCBI | |
Moon EY, Noh YW, Han YH, Kim SU, Kim JM, Yu DY and Lim JS: T lymphocytes and dendritic cells are activated by the deletion of peroxiredoxin II (Prx II) gene. Immunol Lett. 102:184–190. 2006. View Article : Google Scholar : PubMed/NCBI | |
Moon EY, Han YH, Lee DS, Han YM and Yu DY: Reactive oxygen species induced by the deletion of peroxiredoxin II (PrxII) increases the number of thymocytes resulting in the enlargement of PrxII-null thymus. Eur J Immunol. 34:2119–2128. 2004. View Article : Google Scholar : PubMed/NCBI | |
Park JG, Yoo JY, Jeong SJ, Choi JH, Lee MR, Lee MN, Hwa Lee J, Kim HC, Jo H, Yu DY, et al: Peroxiredoxin 2 deficiency exacerbates atherosclerosis in apolipoprotein E-deficient mice. Circ Res. 109:739–749. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kang DH, Lee DJ, Lee KW, Park YS, Lee JY, Lee SH, Koh YJ, Koh GY, Choi C, Yu DY, et al: Peroxiredoxin II is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. Mol Cell. 44:545–558. 2011. View Article : Google Scholar : PubMed/NCBI | |
Balasubramanian P, Vijayarangam V, Deviparasakthi MKG, Palaniyandi T, Ravi M, Natarajan S, Viswanathan S, Baskar G, Wahab MRA and Surendran H: Implications and progression of peroxiredoxin 2 (PRDX2) in various human diseases. Pathol Res Pract. 254:1550802024. View Article : Google Scholar : PubMed/NCBI | |
Wang W, Wei J, Zhang H, Zheng X, Zhou H, Luo Y, Yang J, Deng Q, Huang S and Fu Z: PRDX2 promotes the proliferation of colorectal cancer cells by increasing the ubiquitinated degradation of p53. Cell Death Dis. 12:6052021. View Article : Google Scholar : PubMed/NCBI | |
Jing X, Du L, Niu A, Wang Y, Wang Y and Wang C: Silencing of PRDX2 inhibits the proliferation and invasion of non-small cell lung cancer cells. Biomed Res Int. 2020:12763282020. View Article : Google Scholar : PubMed/NCBI | |
Zhou J, Cheng A, Guo J, Liu Y, Li X, Chen M, Hu D and Wu J: Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: The role of FN1 and the PI3K/AKT/SP1 pathway. J Transl Med. 23:4342025. View Article : Google Scholar : PubMed/NCBI | |
Lee KW, Lee DJ, Lee JY, Kang DH, Kwon J and Kang SW: Peroxiredoxin II restrains DNA damage-induced death in cancer cells by positively regulating JNK-dependent DNA repair. J Biol Chem. 286:8394–8404. 2011. View Article : Google Scholar : PubMed/NCBI | |
Feng AL, Han X, Meng X, Chen Z, Li Q, Shu W, Dai H, Zhu J and Yang Z: PRDX2 plays an oncogenic role in esophageal squamous cell carcinoma via Wnt/β-catenin and AKT pathways. Clin Transl Oncol. 22:1838–1848. 2020. View Article : Google Scholar : PubMed/NCBI | |
Zhan X, Li J, Zeng R, Lei L, Feng A and Yang Z: MiR-92a-2-5p suppresses esophageal squamous cell carcinoma cell proliferation and invasion by targeting PRDX2. Exp Cell Res. 435:1139252024. View Article : Google Scholar : PubMed/NCBI | |
Qi Y, Chiu JF, Wang L, Kwong DLW and He QY: Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics. 5:2960–2971. 2005. View Article : Google Scholar : PubMed/NCBI | |
Yang X, Xiang X, Xu G, Zhou S, An T and Huang Z: Silencing of peroxiredoxin 2 suppresses proliferation and Wnt/β-catenin pathway, and induces senescence in hepatocellular carcinoma. Oncol Res. 32:213–226. 2023. View Article : Google Scholar : PubMed/NCBI | |
Zhao Y, Liu J, Xiong Z, Gu S and Xia X: Exosome-derived miR-23a-5p inhibits HCC proliferation and angiogenesis by regulating PRDX2 expression: MiR-23a-5p/PRDX2 axis in HCC progression. Heliyon. 10:e231682023. View Article : Google Scholar : PubMed/NCBI | |
Zhou S, Han Q, Wang R, Li X, Wang Q, Wang H, Wang J and Ma Y: PRDX2 protects hepatocellular carcinoma SMMC-7721 cells from oxidative stress. Oncol Lett. 12:2217–2221. 2016. View Article : Google Scholar : PubMed/NCBI | |
Bai B, Lin Y, Hu J, Wang H, Li L, Zhao S, Zhang J, Meng W, Yue P, Bai Z and Li X: Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients. Oncol Rep. 41:1539–1548. 2019.PubMed/NCBI | |
Zhang S, He J, Tang M and Sun H: Prdx2 upregulation promotes the growth and survival of gastric cancer cells. Pathol Oncol Res. 26:1869–1877. 2020. View Article : Google Scholar : PubMed/NCBI | |
Chen X, Zhao Y, Luo W, Chen S, Lin F, Zhang X, Fan S, Shen X, Wang Y and Liang G: Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells. Theranostics. 10:10290–10308. 2020. View Article : Google Scholar : PubMed/NCBI | |
Zhou Y, Wang M, Qian Y, Yu D, Zhang J, Fu M, Zhang X, Qin R, Ji R, Zhang X and Gu J: PRDX2 promotes gastric cancer progression by forming a feedback loop with PKM2/STAT3 axis. Cell Signal. 127:1115862025. View Article : Google Scholar : PubMed/NCBI | |
Lu W, Fu Z, Wang H, Feng J, Wei J and Guo J: Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells' survival by protecting cells from oxidative stress. Mol Cell Biochem. 387:261–270. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ji D, Li M, Zhan T, Yao Y, Shen J, Tian H, Zhang Z and Gu J: Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. Carcinogenesis. 34:1265–1272. 2013. View Article : Google Scholar : PubMed/NCBI | |
Peng L, Wang R, Shang J, Xiong Y and Fu Z: Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients. Oncotarget. 8:15057–15070. 2017. View Article : Google Scholar : PubMed/NCBI | |
Lu W, Fu Z, Wang H, Feng J, Wei J and Guo J: Peroxiredoxin 2 knockdown by RNA interference inhibits the growth of colorectal cancer cells by downregulating Wnt/β-catenin signaling. Cancer Lett. 343:190–199. 2014. View Article : Google Scholar : PubMed/NCBI | |
Xu J, Zhang S, Wang R, Wu X, Zeng L and Fu Z: Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway. Biosci Rep. 37:BSR201604472017. View Article : Google Scholar : PubMed/NCBI | |
Chen X, Liao X, Zheng B, Wang F, Chen F, Deng Z, Jiang H and Qin S: Differential plasma proteins identified via iTRAQ-based analysis serve as diagnostic markers of pancreatic ductal adenocarcinoma. Dis Markers. 2023:51451522023. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Zhang L, Lu S, Xiang Y, Zeng C, He T, Ding Y and Wang W: Long non-coding RNA CASC15 promotes intrahepatic cholangiocarcinoma possibly through inducing PRDX2/PI3K/AKT axis. Cancer Res Treat. 53:184–198. 2021. View Article : Google Scholar : PubMed/NCBI | |
Cavalloni G, Peraldo-Neia C, Massa A, Bergamini C, Trentini A, De Rosa G, Daniele L, Ciccosanti F, Cervellati C, Leone F and Aglietta M: Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients. BMC Cancer. 21:8652021. View Article : Google Scholar : PubMed/NCBI | |
Tang Z, Yang Y, Zhang J, Fu W, Lin Y, Su G, Li Y, Meng W, Li X and Xie X: Quantitative proteomic analysis and evaluation of the potential prognostic biomarkers in cholangiocarcinoma. J Cancer. 10:3985–3999. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wonsey DR, Zeller KI and Dang CV: The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA. 99:6649–6654. 2002. View Article : Google Scholar : PubMed/NCBI | |
Huh JY, Kim Y, Jeong J, Park J, Kim I, Huh KH, Kim YS, Woo HA, Rhee SG, Lee KJ and Ha H: Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal. 16:229–243. 2012. View Article : Google Scholar : PubMed/NCBI | |
Song IS, Kim HK, Jeong SH, Lee SR, Kim N, Rhee BD, Ko KS and Han J: Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J Mol Sci. 12:7163–7185. 2011. View Article : Google Scholar : PubMed/NCBI | |
Nonn L, Berggren M and Powis G: Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res. 1:682–689. 2003.PubMed/NCBI | |
Chang TS, Cho CS, Park S, Yu S, Kang SW and Rhee SG: Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem. 279:41975–41984. 2004. View Article : Google Scholar : PubMed/NCBI | |
Lin JF, Xu J, Tian HY, Gao X, Chen QX, Gu Q, Xu GJ, Song JD and Zhao FK: Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer. 121:2596–2605. 2007. View Article : Google Scholar : PubMed/NCBI | |
Liu Z, Hu Y, Liang H, Sun Z, Feng S and Deng H: Silencing PRDX3 inhibits growth and promotes invasion and extracellular matrix degradation in hepatocellular carcinoma cells. J Proteome Res. 15:1506–1514. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chua PJ, Lee EH, Yu Y, Yip GWC, Tan PH and Bay BH: Silencing the peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol. 36:359–364. 2010.PubMed/NCBI | |
Wang YG, Li L, Liu CH, Hong S and Zhang MJ: Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells. Clin Transl Oncol. 16:561–566. 2014. View Article : Google Scholar : PubMed/NCBI | |
Qiao B, Wang J, Xie J, Niu Y, Ye S, Wan Q and Ye Q: Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int J Mol Med. 29:832–840. 2012.PubMed/NCBI | |
Shi L, Wu LL, Yang JR, Chen XF, Zhang Y, Chen ZQ, Liu CL, Chi SY, Zheng JY, Huang HX, et al: Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessemnt of prognosis of hepatocellular carcinoma in Chinese patients. Asian Pac J Cancer Prev. 15:2979–2986. 2014. View Article : Google Scholar : PubMed/NCBI | |
Yan H, Cai X, Fu S, Zhang X and Zhang J: PRDX3 promotes resistance to cisplatin in gastric cancer cells. J Cancer Res Ther. 18:1994–2000. 2022. View Article : Google Scholar : PubMed/NCBI | |
Zhao Z, Cai Z, Zhang S, Yin X, Jiang T, Shen C, Yin Y, Sun H, Chen Z, Han J and Zhang B: Activation of the FOXM1/ASF1B/PRDX3 axis confers hyperproliferative and antioxidative stress reactivity to gastric cancer. Cancer Lett. 589:2167962024. View Article : Google Scholar : PubMed/NCBI | |
Song IS, Jeong YJ and Han J: Mitochondrial metabolism in cancer stem cells: A therapeutic target for colon cancer. BMB Rep. 48:539–540. 2015. View Article : Google Scholar : PubMed/NCBI | |
van Eijck CWF, Strijk G, Vietsch EE, van der Sijde F, Verheij M, Mustafa DAM, Vink M, Aerts JGJV, van Eijck CHJ and Willemsen M: FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction. Eur J Cancer. 196:1134402024. View Article : Google Scholar : PubMed/NCBI | |
Okado-Matsumoto A, Matsumoto A, Fujii J and Taniguchi N: Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. J Biochem. 127:493–501. 2000. View Article : Google Scholar : PubMed/NCBI | |
Tavender TJ, Sheppard AM and Bulleid NJ: Peroxiredoxin IV is an endoplasmic reticulum-localized enzyme forming oligomeric complexes in human cells. Biochem J. 411:191–199. 2008. View Article : Google Scholar : PubMed/NCBI | |
Wang X, Wang L, Wang X, Sun F and Wang CC: Structural insights into the peroxidase activity and inactivation of human peroxiredoxin 4. Biochem J. 441:113–118. 2012. View Article : Google Scholar : PubMed/NCBI | |
Wood ZA, Poole LB, Hantgan RR and Karplus PA: Dimers to doughnuts: Redox-sensitive oligomerization of 2-cysteine peroxiredoxins. Biochemistry. 41:5493–5504. 2002. View Article : Google Scholar : PubMed/NCBI | |
Cao Z, Tavender TJ, Roszak AW, Cogdell RJ and Bulleid NJ: Crystal structure of reduced and of oxidized peroxiredoxin IV enzyme reveals a stable oxidized decamer and a non-disulfide-bonded intermediate in the catalytic cycle. J Biol Chem. 286:42257–42266. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ito R, Takahashi M, Ihara H, Tsukamoto H, Fujii J and Ikeda Y: Measurement of peroxiredoxin-4 serum levels in rat tissue and its use as a potential marker for hepatic disease. Mol Med Rep. 6:379–384. 2012. View Article : Google Scholar : PubMed/NCBI | |
Leyens G, Donnay I and Knoops B: Cloning of bovine peroxiredoxins-gene expression in bovine tissues and amino acid sequence comparison with rat, mouse and primate peroxiredoxins. Comp Biochem Physiol B Biochem Mol Biol. 136:943–955. 2003. View Article : Google Scholar : PubMed/NCBI | |
Schulte J, Struck J, Bergmann A and Köhrle J: Immunoluminometric assay for quantification of peroxiredoxin 4 in human serum. Clin Chim Acta. 411:1258–1263. 2010. View Article : Google Scholar : PubMed/NCBI | |
Zito E: PRDX4, an endoplasmic reticulum-localized peroxiredoxin at the crossroads between enzymatic oxidative protein folding and nonenzymatic protein oxidation. Antioxid Redox Signal. 18:1666–1674. 2013. View Article : Google Scholar : PubMed/NCBI | |
Rhee SG: Cell signaling. H2O2, a necessary evil for cell signaling. Science. 312:1882–1883. 2006. View Article : Google Scholar : PubMed/NCBI | |
Wang W, Shen XB, Huang DB, Jia W, Liu WB and He YF: Peroxiredoxin 4 suppresses anoikis and augments growth and metastasis of hepatocellular carcinoma cells through the β-catenin/ID2 pathway. Cell Oncol (Dordr). 42:769–781. 2019. View Article : Google Scholar : PubMed/NCBI | |
Kim TH, Song J, Alcantara Llaguno SR, Murnan E, Liyanarachchi S, Palanichamy K, Yi JY, Viapiano MS, Nakano I, Yoon SO, et al: Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth. PLoS One. 7:e428182012. View Article : Google Scholar : PubMed/NCBI | |
Kobayashi S, Hiwasa T, Arasawa T, Kagaya A, Ishii S, Shimada H, Ito M, Suzuki M, Kano M, Rahmutulla B, et al: Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library. Oncotarget. 9:18559–18569. 2018. View Article : Google Scholar : PubMed/NCBI | |
Guo X, Noguchi H, Ishii N, Homma T, Hamada T, Hiraki T, Zhang J, Matsuo K, Yokoyama S, Ishibashi H, et al: The association of peroxiredoxin 4 with the initiation and progression of hepatocellular carcinoma. Antioxid Redox Signal. 30:1271–1284. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zhang L, Wu K, Hou Y and Li X: Validation of the interaction between PRDX4 and TXNDC5 in gastric cancer and the significance of the PRDX4 gene in gastric cancer based on a data mining analysis. Transl Cancer Res. 13:81–101. 2024. View Article : Google Scholar : PubMed/NCBI | |
Park SY, Lee YJ, Park J, Kim TH, Hong SC, Jung EJ, Ju YT, Jeong CY, Park HJ, Ko GH, et al: PRDX4 overexpression is associated with poor prognosis in gastric cancer. Oncol Lett. 19:3522–3530. 2020.PubMed/NCBI | |
Jia W, Chen P and Cheng Y: PRDX4 and its roles in various cancers. Technol Cancer Res Treat. 18:15330338198643132019. View Article : Google Scholar : PubMed/NCBI | |
Yi N, Xiao MB, Ni WK, Jiang F, Lu CH and Ni RZ: High expression of peroxiredoxin 4 affects the survival time of colorectal cancer patients, but is not an independent unfavorable prognostic factor. Mol Clin Oncol. 2:767–772. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhou H, Li L, Chen J, Hou S, Zhou T and Xiong Y: Expression and prognostic value of PRDX family in colon adenocarcinoma by integrating comprehensive analysis and in vitro and in vivo validation. Front Oncol. 13:11367382023. View Article : Google Scholar : PubMed/NCBI | |
Han J, Itoh T, Shioya A, Sakurai M, Oyama T, Kumagai M, Takamura H, Okuro M, Mukai T, Kitakata H, et al: The combination of the low immunohistochemical expression of peroxiredoxin 4 and perilipin 2 predicts longer survival in pancreatic ductal adenocarcinoma with peroxiredoxin 4 possibly playing a main role. Histol Histopathol. 38:1415–1427. 2023.PubMed/NCBI | |
Ma P, Zhou Y, Fang P, Ke W, Xiao S and Fang L: Molecular cloning, prokaryotic expression and the anti-inflammatory activity of porcine PRDX5. Dev Comp Immunol. 136:1045152022. View Article : Google Scholar : PubMed/NCBI | |
Seo MS, Kang SW, Kim K, Baines IC, Lee TH and Rhee SG: Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J Biol Chem. 275:20346–20354. 2000. View Article : Google Scholar : PubMed/NCBI | |
Ji Y, Chae S, Lee HK, Park I, Kim C, Ismail T, Kim Y, Park JW, Kwon OS, Kang BS, et al: Peroxiredoxin5 controls vertebrate ciliogenesis by modulating mitochondrial reactive oxygen species. Antioxid Redox Signal. 30:1731–1745. 2019. View Article : Google Scholar : PubMed/NCBI | |
Agborbesong E, Zhou JX, Li LX, Calvet JP and Li X: Antioxidant enzyme peroxiredoxin 5 regulates cyst growth and ciliogenesis via modulating Plk1 stability. FASEB J. 36:e220892022. View Article : Google Scholar : PubMed/NCBI | |
Knoops B, Goemaere J, Van der Eecken V and Declercq JP: Peroxiredoxin 5: Structure, mechanism, and function of the mammalian atypical 2-Cys peroxiredoxin. Antioxid Redox Signal. 15:817–829. 2011. View Article : Google Scholar : PubMed/NCBI | |
Chen X, Cao X, Xiao W, Li B and Xue Q: PRDX5 as a novel binding partner in Nrf2-mediated NSCLC progression under oxidative stress. Aging (Albany NY). 12:122–137. 2020. View Article : Google Scholar : PubMed/NCBI | |
Bai F, Zhang N, Fang W, He X, Zheng Y and Gu D: PCAT6 mediates cellular biological functions in gastrointestinal stromal tumor via upregulation of PRDX5 and activation of Wnt pathway. Mol Carcinog. 59:661–669. 2020. View Article : Google Scholar : PubMed/NCBI | |
Xie DP, Gong YX, Lee J, Jeong EM, Ren CX, Guo XY, Han YH, Cui YD, Lee SJ, Kwon T and Sun HN: Peroxiredoxin 5 protects HepG2 cells from ethyl β-carboline-3-carboxylate-induced cell death via ROS-dependent MAPK signalling pathways. J Cancer. 13:3258–3267. 2022. View Article : Google Scholar : PubMed/NCBI | |
Qi W, Li Z, Xia L, Dai J, Zhang Q, Wu C and Xu S: LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cells. Sci Rep. 9:161852019. View Article : Google Scholar : PubMed/NCBI | |
Kim B, Kim YS, Ahn HM, Lee HJ, Jung MK, Jeong HY, Choi DK, Lee JH, Lee SR, Kim JM and Lee DS: Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer. Int J Oncol. 51:298–306. 2017. View Article : Google Scholar : PubMed/NCBI | |
Jin YZ, Gong YX, Liu Y, Xie DP, Ren CX, Lee SJ, Sun HN, Kwon T and Xu DY: Peroxiredoxin V silencing elevates susceptibility to doxorubicin-induced cell apoptosis via ROS-dependent mitochondrial dysfunction in AGS gastric cancer cells. Anticancer Res. 41:1831–1840. 2021. View Article : Google Scholar : PubMed/NCBI | |
Ahn HM, Yoo JW, Lee S, Lee HJ, Lee HS and Lee DS: Peroxiredoxin 5 promotes the epithelial-mesenchymal transition in colon cancer. Biochem Biophys Res Commun. 487:580–586. 2017. View Article : Google Scholar : PubMed/NCBI | |
Arevalo JA and Vazquez-Medina JP: The role of peroxiredoxin 6 in cell signaling. Antioxidants (Basel). 7:1722018. View Article : Google Scholar : PubMed/NCBI | |
Fisher AB: The phospholipase A2 activity of peroxiredoxin 6. J Lipid Res. 59:1132–1147. 2018. View Article : Google Scholar : PubMed/NCBI | |
Wahlig S, Lovatt M and Mehta JS: Functional role of peroxiredoxin 6 in the eye. Free Radic Biol Med. 126:210–220. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kumari A, Chowhan RK, Kakchingtabam P, Shahnaj S, Rahaman H, Ansari MS and Singh LR: Peroxiredoxin-6: A guardian of lung pathophysiologies. Curr Protein Pept Sci. 22:666–674. 2021. View Article : Google Scholar : PubMed/NCBI | |
Tu Q, Xiong Y, Fan L, Qiao B, Xia Z, Hu L, Wang Y, Peng G and Ye Q: Peroxiredoxin 6 attenuates ischemia- and hypoxia-induced liver damage of brain-dead donors. Mol Med Rep. 13:753–761. 2016. View Article : Google Scholar : PubMed/NCBI | |
Manevich Y and Fisher AB: Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med. 38:1422–1432. 2005. View Article : Google Scholar : PubMed/NCBI | |
Raatikainen S, Aaaltomaa S, Kärjä V and Soini Y: Increased peroxiredoxin 6 expression predicts biochemical recurrence in prostate cancer patients after radical prostatectomy. Anticancer Res. 35:6465–6470. 2015.PubMed/NCBI | |
Fisher AB: Peroxiredoxin 6: A bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities. Antioxid Redox Signal. 15:831–844. 2011. View Article : Google Scholar : PubMed/NCBI | |
Huang WS, Huang CY, Hsieh MC, Kuo YH, Tung SY, Shen CH, Hsieh YY, Teng CC, Lee KC, Lee KF and Kuo HC: Expression of PRDX6 correlates with migration and invasiveness of colorectal cancer cells. Cell Physiol Biochem. 51:2616–2630. 2018. View Article : Google Scholar : PubMed/NCBI | |
Yun HM, Park KR, Lee HP, Lee DH, Jo M, Shin DH, Yoon DY, Han SB and Hong JT: PRDX6 promotes lung tumor progression via its GPx and iPLA2 activities. Free Radic Biol Med. 69:367–376. 2014. View Article : Google Scholar : PubMed/NCBI | |
Mu R, Li Y, Xing J, Li Y, Lin R, Ye S, Zhang Y, Mu H, Guo X and An L: Effect of lentivirus-mediated peroxiredoxins 6 gene silencing on the phenotype of human gastric cancer BGC-823 cells. J Cancer Res Ther. 18:411–417. 2022. View Article : Google Scholar : PubMed/NCBI | |
Guo JH, Xing GL, Fang XH, Wu HF, Zhang B, Yu JZ, Fan ZM and Wang LD: Proteomic profiling of fetal esophageal epithelium, esophageal cancer, and tumor-adjacent esophageal epithelium and immunohistochemical characterization of a representative differential protein, PRX6. World J Gastroenterol. 23:1434–1442. 2017. View Article : Google Scholar : PubMed/NCBI | |
He Y, Xu W, Xiao Y, Pan L, Chen G, Tang Y, Zhou J, Wu J, Zhu W, Zhang S and Cao J: Overexpression of peroxiredoxin 6 (PRDX6) promotes the aggressive phenotypes of esophageal squamous cell carcinoma. J Cancer. 9:3939–3949. 2018. View Article : Google Scholar : PubMed/NCBI | |
Mu R, Chang M, Feng C, Cui Y, Li T, Liu C, Wang Y and Guo X: Analysis of the expression of PRDX6 in patients with hepatocellular carcinoma and its effect on the phenotype of hepatocellular carcinoma cells. Curr Genomics. 25:2–11. 2024. View Article : Google Scholar : PubMed/NCBI | |
Xu X, Lu D, Zhuang R, Wei X, Xie H, Wang C, Zhu Y, Wang J, Zhong C, Zhang X, et al: The phospholipase A2 activity of peroxiredoxin 6 promotes cancer cell death induced by tumor necrosis factor alpha in hepatocellular carcinoma. Mol Carcinog. 55:1299–1308. 2016. View Article : Google Scholar : PubMed/NCBI | |
Choi H, Chang JW and Jung YK: Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase. Cell Death Differ. 18:405–414. 2011. View Article : Google Scholar : PubMed/NCBI | |
Guo HW, Lü YY, Zhu YL and Yang GB: Expression of peroxiredoxin 6 in gastric cancer and its clinical significance. Zhonghua Yi Xue Za Zhi. 92:2433–2435. 2012.(In Chinese). PubMed/NCBI | |
Wang D, Li Y, Liu Y, Cheng S, Liu F, Zuo R, Ding C, Shi S and Liu G: NPM1 promotes cell proliferation by targeting PRDX6 in colorectal cancer. Int J Biochem Cell Biol. 147:1062332022. View Article : Google Scholar : PubMed/NCBI | |
Lagal DJ, Montes-Osuna AM, Ortiz-Olivencia A, Arribas-Parejas C, Ortiz-Alcántara Á, Pescuezo-Castillo C, Bárcena JA, Padilla CA and Requejo-Aguilar R: Tumoral malignancy decreases coupled with higher ROS and lipid peroxidation in HCT116 colon cancer cells upon loss of PRDX6. Antioxidants (Basel). 13:8812024. View Article : Google Scholar : PubMed/NCBI | |
Huang WS, Kuo YH, Chin CC, Wang JY, Yu HR, Sheen JM, Tung SY, Shen CH, Chen TC, Sung ML, et al: Proteomic analysis of the effects of baicalein on colorectal cancer cells. Proteomics. 12:810–819. 2012. View Article : Google Scholar : PubMed/NCBI | |
Park JY, Kim SA, Chung JW, Bang S, Park SW, Paik YK and Song SY: Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer. J Cancer Res Clin Oncol. 137:1229–1238. 2011. View Article : Google Scholar : PubMed/NCBI | |
Li H, Wu Z, Zhong R, Zhang Q, Chen Q and Shen Y: PRDX6 knockout restrains the malignant progression of intrahepatic cholangiocarcinoma. Med Oncol. 39:2502022. View Article : Google Scholar : PubMed/NCBI |